Powered by
ROYAL OAK—Immunis.AI Inc., a biotech company developing noninvasive blood-based tests for disease, announced the publication of pivotal results from its clinical trial, Evaluation of an RNAseq-based Immunogenomic Liquid Biopsy Approach …
CANTON TWP.—Officials at MMS Holdings, the Canton Township-based contract pharmaceutical research firm, announced that the company’s MMS Academy has launched new courses in inspection readiness and clinical programming for clinical …
ANN ARBOR—Esperion Therapeutics Inc. (Nasdaq: ESPR), the Ann Arbor-based developer of cholesterol-lowering drugs, announced that the results of a Phase 2 study evaluating the combination of its Nexletol (bempedoic acid) …
PRINCETON, N.J.—Certara (Nasdaq: CERT), the New Jersey-based biosimulation company, has licensed the Anonymize software to anonymize clinical data from Canton Township-based TrialAssure. TrialAssure’s Anonymize allows clinical trial sponsors to anonymize …
CANTON TWP.–MMS Holdings, a contract research organization for the pharmaceutical industry, has joined the Decentralized Trials and Research Alliance, an organization launched in December to unite healthcare companies, regulators, patient …
LOS ANGELES—Officials at the St. Baldrick’s Foundation has named two Michigan hospitals among 17 grant winners of $819,000 in grants to advance research into children’s cancers. The Los Angeles-based foundation …
DETROIT—Officials at the Karmanos Cancer Institute in Detroit have announced the launch of a new clinical trials study information portal (SIP) at www.karmanos.org/opentrials. The SIP website, which is integrated with …
ANN ARBOR—HistoSonics Inc. announced that it had received an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA) to begin a clinical trial of its new technology, …
CANTON TWP.—MMS Holdings Inc. said that its collaboration with Shanghai-based Green Valley Pharmaceutical Co. resulted in gaining U.S. Food & Drug Administration approval of an Investigational New Drug application for …
DETROIT—An oral therapy that has been studied in laboratory experiments and clinical trials at the Barbara Ann Karmanos Cancer Institute, in partnership with Karyopharm Therapeutics Inc., will soon enter clinical …